AntriaBio raises $6.7M, plans to file new drug application

LOUISVILLE — AntriaBio Inc. (OTC: ANTB), a pharmaceutical company that specializes in developing drug therapies for patients with diabetes and metabolic diseases, has raised $6.7 million.

The Louisville-based company is seeking to raise $15 million, according to a Form D filed with the Securities and Exchange Commission on May 30.

AntriaBio did not return requests for comment.

The company has 45 employees. Its main product, according to its website, is AB101, a once-a-week basal insulin for patients with Type 1 and Type 2 diabetes.

In early May, AntriaBio launched the first in-human study of AB101. The company said it plans to file a new drug application with the FDA this month.

LOUISVILLE — AntriaBio Inc. (OTC: ANTB), a pharmaceutical company that specializes in developing drug therapies for patients with diabetes and metabolic diseases, has raised $6.7 million.

The Louisville-based company is seeking to raise $15 million, according to a Form D filed with the Securities and Exchange Commission on May 30.

AntriaBio did not return requests for comment.

The company has 45 employees. Its main product, according to its website, is AB101, a once-a-week basal insulin for patients with Type 1 and Type 2 diabetes.

In early May, AntriaBio launched the first in-human study of AB101. The company said it plans to file a new drug application with the FDA this month.